Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCR for Poor-Prognosis Chronic GvHD
NCT01001780Phase 2Withdrawn
- Sponsor
- University of Rochester
- Start
- Aug 2009
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of pentostatin, cyclophosphamide, rituximab in chronic graft-versus-host disease (cGVHD), sponsored by University of Rochester. Planned start Aug 2009; status: withdrawn.
02
Drugs
pentostatincyclophosphamiderituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT01001780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001780.